Bank Ups Affymetrix Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Thomas Weisel Partners has increased its fourth-quarter and full-year 2009 revenue guidance for Affymetrix, two weeks before the firm is scheduled to report its results.

Analyst Peter Lawson said that the bank has increased its Q4 estimate to $83 million from its previous estimate of $82 million, slightly above analysts' consensus estimate of $82.8 million. It also lowered the firm's loss per share to $.10 from $.11, in line with the consensus estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.